Search Results - "Vidarsdottir, Linda"

Targeting Plk1 with siRNNs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients by Goroshchuk, Oksana, Vidarsdottir, Linda, Björklund, Ann-Charlotte, Hamil, Alexander S., Kolosenko, Iryna, Dowdy, Steven F., Palm-Apergi, Caroline

“…B-cell acute lymphoblastic leukemia (B-ALL) accounts for nearly one fifth of all childhood cancers and current challenges in B-ALL treatment include…”
Get full text

MicroRNA-190b Targets RFWD3 in Estrogen Receptor-Positive Breast Cancer by Frick, Elisabet Alexandra, Kristjansdottir, Karen, Ragnarsdottir, Snaedís, Vilhjalmsson, Arnar Ingi, Bustos, Maria Rose, Vidarsdottir, Linda, Gudjonsson, Thorkell, Sigurdsson, Stefan

“…In the year 2020, breast cancer was the most common form of cancer worldwide. Roughly 70% of breast cancers are estrogen receptor-positive (ER+). MicroRNA-190b…”
Get full text

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma by Vidarsdottir, Linda, Azimi, Alireza, Das, Ishani, Sigvaldadottir, Ingibjorg, Suryo Rahmanto, Aldwin, Petri, Andreas, Kauppinen, Sakari, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Frostvik Stolt, Marianne, Tuominen, Rainer, Sangfelt, Olle, Pokrovskaja Tamm, Katja, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Johnsson, Per

“…BRAF inhibitors (BRAFi) selectively target oncogenic BRAF V600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600…”
Get full text

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers by Tryggvadóttir, Laufey, Vidarsdóttir, Linda, Thorgeirsson, Tryggvi, Jonasson, Jon Gunnlaugur, Ólafsdóttir, Elinborg Jona, Ólafsdóttir, Gudridur Helga, Rafnar, Thorunn, Thorlacius, Steinunn, Jonsson, Eirikur, Eyfjord, Jorunn Erla, Tulinius, Hrafn

“…Background Mutations in the BRCA2 gene are associated with an increased risk of prostate cancer, but it is not known whether they are associated with…”
Get full text

Estrogen receptor-positive breast cancer and adverse outcome in BRCA2 mutation carriers and young non-carrier patients by Vidarsdottir, Linda, Olafsdottir, Elinborg J., Barkardottir, Rosa B., Bjarnadottir, Olöf, Jonasson, Jon G., Sigurdsson, Stefan, Tryggvadottir, Laufey

“…Estrogen receptor-positive (ER+) breast cancer generally confers a more favorable prognosis than ER-negative cancer, however, a different picture is emerging…”
Get full text

The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene by Lister, Nicholas, Shevchenko, Galina, Walshe, James L., Groen, Jessica, Johnsson, Per, Vidarsdóttir, Linda, Grander, Dan, Ataide, Sandro F., Morris, Kevin V.

“…RNA has been found to interact with chromatin and modulate gene transcription. In human cells, little is known about how long noncoding RNAs (lncRNAs) interact…”
Get full text

Polo-like kinases and acute leukemia by Goroshchuk, Oksana, Kolosenko, Iryna, Vidarsdottir, Linda, Azimi, Alireza, Palm-Apergi, Caroline

“…Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic…”
Get full text

Thermal proteome profiling identifies PIP4K2A and ZADH2 as off‐targets of Polo‐like kinase 1 inhibitor volasertib by Goroshchuk, Oksana, Kolosenko, Iryna, Kunold, Elena, Vidarsdottir, Linda, Pirmoradian, Mohammad, Azimi, Alireza, Jafari, Rozbeh, Palm‐Apergi, Caroline

“…Polo‐like kinase 1 (PLK1) is an important cell cycle kinase and an attractive target for anticancer treatments. An ATP‐competitive small molecular PLK1…”
Get full text

RNAi prodrugs decrease elevated mRNA levels of Polo‐like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients by Kolosenko, Iryna, Goroshchuk, Oksana, Vidarsdottir, Linda, Björklund, Ann‐Charlotte, Dowdy, Steven F., Palm‐Apergi, Caroline

“…Polo‐like kinase 1 (Plk1) is an important regulator of the cell cycle and it is frequently overexpressed in cancer cells. Several small molecule inhibitors…”
Get full text

ALL-166: Novel RNAi Prodrugs Targeting Plk1 Induce Specific mRNA Cleavage in Pediatric Acute B-Cell Lymphoblastic Leukemia by Goroshchuk, Oksana, Vidarsdottir, Linda, Björklund, Ann-Charlotte, Hamil, Alexander, Kolosenko, Iryna, Dowdy, Steven, Palm-Apergi, Caroline

“…Acute B-cell lymphoblastic leukemia (B-cell ALL) is a predominant malignancy among children of different ages. Despite the efficiency of the existing drugs, up…”
Get full text

Designing siRNA and Evaluating Its Effect on RNA Targets Using qPCR and Western Blot by Vidarsdottir, Linda, Goroshchuk, Oksana, Kolosenko, Iryna, Palm-Apergi, Caroline

“…The discovery of the RNA interference (RNAi) pathway followed by the usage of synthetic short-interfering RNAs (siRNA) has contributed greatly to the…”
Get more information

A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in human cells by Johnsson, Per, Ackley, Amanda, Vidarsdottir, Linda, Lui, Weng-Onn, Corcoran, Martin, Grandér, Dan, Morris, Kevin V

“…The PTEN tumor-suppressor gene is regulated by the PTENpg1 long noncoding RNA. A new study investigating a previously uncharacterized PTENpg1-encoded antisense…”
Get full text

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib by Vidarsdottir, Linda, Fernandes, Rita Valador, Zachariadis, Vasilios, Das, Ishani, Edsbäcker, Elin, Sigvaldadottir, Ingibjorg, Azimi, Alireza, Höiom, Veronica, Hansson, Johan, Grandér, Dan, Egyházi Brage, Suzanne, Pokrovskaja Tamm, Katja

“…Introduction of targeted therapy in the treatment of metastatic cutaneous malignant melanoma (CMM) has improved clinical outcome during the last years…”
Get full text

Abstract B28: PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts clinical outcome in melanoma patients by Vidarsdottir, Linda, Azimi, Alireza, Serviss, Jason, Ingvar, Christian, Jönsson, Göran, Olsson, Håkan, Stolt, Marianne Frostvik, Hansson, Johan, Brage, Suzanne Egyházi, Grandér, Dan, Johnsson, Per

“…Approximately 50% of cutaneous melanomas carry activating mutations in the serine/threonine protein kinase BRAF. Vemurafenib is a highly potent inhibitor of…”
Get full text

Sensitivity of BRCA2 mutated human cell lines to Aurora kinase inhibition by Vidarsdottir, Linda, Steingrimsdottir, Gudridur, Bodvarsdottir, Sigridur Klara, Ogmundsdottir, Helga Margret, Eyfjord, Jorunn Erla

“…Summary Aurora kinases play a vital part in successful mitosis and cell division. Aberrant Aurora-A and -B expression is commonly seen in various types of…”
Get full text

Breast cancer risk associated with AURKA 91T → A polymorphism in relation to BRCA mutations by Vidarsdottir, Linda, Bodvarsdottir, Sigridur K, Hilmarsdottir, Holmfridur, Tryggvadottir, Laufey, Eyfjord, Jorunn E

“…Abstract In this study 759 breast cancer patients, including 9 BRCA1 and 98 BRCA2 mutation carriers, and 653 mutation-negative unaffected controls were…”
Get full text

AURKA and breast cancer in BRCA1/2 mutation carriers by Bodvarsdottir, Sigridur K, Vidarsdottir, Linda, Eyfjord, Jorunn E

Get full text